Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications
Source abstract
Abstract
Immune enhancement is a central objective in modern immunotherapy, vaccination, and regenerative medicine; however, achieving a powerful, sustained immune response while reducing overall systemic toxicity remains a major challenge. Organic biomaterials (OBs) are effective immunobioengineering platforms characterized by biocompatibility, tunable physicochemical properties, and the ability to deliver therapeutic cargo at localized, sustained doses; however, most exhibit low intrinsic immunostimulatory activity. Integrating nanoscale adjuvants into OB matrices has therefore emerged as an effective strategy to amplify immune activation by regulating immune recognition, cellular uptake, intracellular trafficking, and downstream signaling pathways. This review presents a mechanistic framework for nanoadjuvant-integrated OBs, focusing on biointerface-mediated immune sensing, complement activation, cellular internalization pathways, and antigen processing and presentation. We have summarized the major classes of natural and synthetic biomaterials, representative nanoadjuvant platforms, and key nanoengineering parameters, including particle size, surface chemistry, mechanical properties, and spatiotemporal release kinetics, that govern immune potency, polarization, and safety. Particular emphasis is placed on molecular mechanisms involving pattern recognition receptor signaling, inflammasome activation, cytokine regulation, immunometabolic reprogramming, and epigenetic remodeling of immune cells. Finally, we have discussed the translational potential of these systems for cancer immunotherapy, vaccination, regenerative medicine, and immune-inflammatory diseases, while highlighting key challenges related to immunotoxicity, biodistribution, manufacturing scalability, and regulatory translation. We have also provided mechanistic insights and rational design principles for the development of next-generation nanoadjuvant biomaterials for immune engineering.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies10.1097/MOH.0000000000000559 ↗
2. Innate immune cells and their contribution to T-Cell-Based immunotherapy. International journal of molecular sciences
3. A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells. International journal of molecular sciences
4. Tumors resurrect an embryonic vascular program to escape immunity
5. Hypertension: do inflammation and immunity hold the key to solving this epidemic?10.1161/CIRCRESAHA.121.318052 ↗
6. Therapeutic targeting of trained immunity10.1038/s41573-019-0025-4 ↗
7. Mitigating the toxic effects of anticancer immunotherapy. Nature reviews clinical oncology
8. The anticancer immune response: indispensable for therapeutic success?10.1172/JCI35180 ↗
9. In situ crosslinked hydrogel depot for sustained antibody release improves immune checkpoint blockade cancer immunotherapy10.3390/nano11020471 ↗
10. Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: insights from islets and beyond10.1016/j.addr.2023.115050 ↗
11. Recent applications of immunomodulatory biomaterials for disease immunotherapy10.1002/EXP.20210157 ↗
12. Stimuli-responsive biomaterials for vaccines and immunotherapeutic applications. Advanced therapeutics
13. Hemocompatibility of degrading polymeric biomaterials: degradable polar hydrophobic ionic polyurethane versus poly(lactic-co-glycolic10.1021/acs.biomac.7b00456 ↗
14. Advances and challenges in polymer-based scaffolds for bone tissue engineering: a path towards personalized regenerative medicine10.3390/polym16233303 ↗
15. Barbery · Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems. 16 · 2025
16. Collagen-based biomaterials as 3D scaffold for cell cultures: applications for tissue engineering and gene therapy. Medical & biological engineering & computing
17. Biomaterials for personalized cell therapy10.1002/adma.201902005 ↗
18. Sarkar · 2016
19. Immunomodulatory biomaterials: tailoring surface properties to mitigate foreign body reaction and enhance tissue regeneration
20. Activation of macrophages in response to biomaterials. Results and problems in cell differentiation
21. Engineering the immune response to biomaterials
22. Tumor microenvironment-responsive manganese-based nano-modulator activate the cGAS-STING pathway to enhance innate immune system response
23. Biomaterials for nanoparticle vaccine delivery systems10.1007/s11095-014-1419-y ↗
24. From antigen delivery system to adjuvanticy: the board application of nanoparticles in vaccinology10.3390/vaccines3040930 ↗
25. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. Journal of materials chemistry B
26. Immunogenicity of different types of adjuvants and nano-adjuvants in veterinary vaccines: a comprehensive review10.3390/vaccines11020453 ↗
27. STIM1 promotes migration, phagosomal maturation and antigen cross-presentation in dendritic cells
28. In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells10.1016/j.nantod.2024.102518 ↗
29. Engineered plant-derived nanovesicles facilitate tumor therapy: natural bioactivity plus drug controlled release platform. Int J nanomedicine
30. A polymer-based antigen carrier activates two innate immune pathways for adjuvant-free subunit vaccines. ACS nano
31. Hydrogel-by-design: smart delivery system for cancer immunotherapy
32. Injectable hydrogel-based combination cancer immunotherapy for overcoming localized therapeutic efficacy
33. Beyond antigens and adjuvants: formulating future vaccines. Journal of clinical investigation
34. Lanis · Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy. · 2025 · 11 · 889
35. Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. Journal of pharmaceutical investigation
36. Smart polymeric nanoparticles in cancer immunotherapy10.3390/pharmaceutics15030775 ↗
37. Nanomaterials in immunology: bridging innovative approaches in immune modulation, diagnostics, and therapy. Journal of functional biomaterials
38. Emerging concepts in the science of vaccine adjuvants10.1038/s41573-021-00163-y ↗
39. Responsive cell-material interfaces. Nanomedicine
40. Engineering DNA nanostructures to manipulate immune receptor signaling and immune cell fates. Advanced healthcare materials
41. Recent biomaterial-assisted approaches for immunotherapeutic inhibition of cancer recurrence. ACS biomaterials science & engineering
42. Cell-targeted vaccines: implications for adaptive immunity. Frontiers in immunology
43. Next-generation subunit vaccine delivery systems: design, applications, and prospects
44. Hydrophilic titanium surfaces reduce neutrophil inflammatory response and NETosis10.1039/C9BM01474H ↗
45. Modulation of immune-inflammatory responses through surface modifications of biomaterials to promote bone healing and regeneration
46. Exploring dendritic cell subtypes in cancer immunotherapy: unraveling the role of mature regulatory dendritic cells. Upsala journal of medical sciences
47. Tailoring biomaterials for vaccine delivery10.1186/s12951-024-02758-0 ↗
48. A “trained immunity” inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice
49. Use of dendritic cell receptors as targets for enhancing anti-cancer immune responses10.3390/cancers11030418 ↗
50. Research progress on dendritic cells in hepatocellular carcinoma immune microenvironments10.3390/biom14091161 ↗
51. MHC class II presentation in autoimmunity. Cells
52. Antigen presentation and autophagy in teleost adaptive immunity. International journal of molecular sciences
53. Next-generation antigen-presenting cell immune therapeutics for gliomas
54. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature
55. Biomaterials direct functional B cell response in a material-specific manner
56. Engineering biomaterials to direct innate immunity10.1002/adtp.201800157 ↗
57. Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis
58. Engineered bacteria-nanoparticle conjugate reprograms immunosuppressive niche via dendritic cell-centric innate-adaptive immune coupling. ACS nano
59. Effect of sialic acid loss on dendritic cell maturation10.1111/j.1365-2567.2009.03047.x ↗
60. The role of dendritic cell maturation in the induction of insulin-dependent diabetes mellitus
61. Implantable and injectable biomaterial scaffolds for cancer immunotherapy. Frontiers in bioengineering and biotechnology
62. The role of dendritic cells in the immunomodulation to implanted biomaterials. International journal of oral science
63. Plasmacytoid dendritic cells control T-cell response to chronic viral infection10.1073/pnas.1117359109 ↗
64. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. Proceedings of the national academy of sciences
65. Plasmacytoid dendritic cells in dermatology. Anais Brasileiros de Dermatologia
66. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases10.1038/nri2358 ↗
67. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells10.4049/jimmunol.179.11.7767 ↗
68. Acute Penicillium marneffei infection stimulates host M1/M2a macrophages polarization in BALB/C mice
69. EGFR of platelet regulates macrophage activation and bacterial phagocytosis function
70. Chronically elevated O-GlcNAcylation limits nitric oxide production and deregulates specific pro-inflammatory cytokines
71. Advanced age impairs macrophage polarization. Journal of interferon & cytokine research
72. Integrin-mediated interactions control macrophage polarization in 3D hydrogels. Advanced healthcare materials
73. Macrophage polarization and reprogramming in acute inflammation: a redox perspective10.3390/antiox11071394 ↗
74. Myeloperoxidase transforms chromatin into neutrophil extracellular traps10.1038/s41586-025-09523-9 ↗
75. Natural killer cell and macrophage cooperation in MyD88-dependent innate responses to plasmodium falciparum. Proceedings of the national academy of sciences
76. Metabolism of NK cells during viral infections
77. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis
78. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway
79. DNA sensing in the innate immune response. Physiology
80. The role of the cGAS-STING signaling pathway in viral infections, inflammatory and autoimmune diseases10.1038/s41401-023-01185-5 ↗
81. Modulation of immune responses through direct activation of toll-like receptors to T cells. Clinical and experimental immunology
82. Potential adjuvantic properties of innate immune stimuli10.4161/hv.5.6.8175 ↗
83. Type 2 innate immune responses and the natural helper cell. Immunology
84. CD4 T helper cell subsets and related human immunological disorders. International journal of molecular sciences
85. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release10.1046/j.1365-2567.2003.01569.x ↗
86. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrology dialysis transplantation
87. Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice
88. The T helper 17-regulatory T cell axis in transplant rejection and tolerance10.1097/MOT.0b013e32832ce88e ↗
89. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunological reviews
90. CD4+ Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal immunology
91. Granzyme B produced by natural killer cells enhances inflammatory response and contributes to the immunopathology of cutaneous leishmaniasis. The journal of infectious diseases
92. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. The journal of immunology
93. CD6 is a target for cancer immunotherapy
94. Immune checkpoints in B cells: unlocking new potentials in cancer treatment
95. B cell-based cancer immunotherapy. Transfusion medicine and hemotherapy
96. Insights from analysis of human antigen-specific memory B cell repertoires
97. Indirect impact of PD-1/PD-L1 blockade on a murine model of NK cell exhaustion
98. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
99. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines10.4161/onci.26013 ↗
100. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. Science